Resistell Antibiotic Susceptibility Test
World's fastest phenotypic Antibiotic Susceptibility Test
Resistell’s rapid AST is growth independent. It reduces time to result from days to a few hours. It enables targeted use of antibiotics from day one.
- Antimicrobial stewardship
- Microbial diagnostics
- Infection prevention
- Antimicrobial compound/strategy
- Removal antibiotics/bacteria
Microorganisms:
- Bacteria
- Fungi
- Yeasts
- Viruses
- Parasites
Application:
- Human
- Veterinary
- AgriFood
- Environmental
- Other
Development stage:
- Validation
- Market entry
- Research
- Development
- Marketed product
- Company
- Academia
- Institute
- NGO
- Government
Partnering:
- License
- Co-develop
- Joint Venture
- Sell
- Outsource
Funding organisation:
- OTHER / NA
- CARB-X
- FIND
- GARDP
- REPAIR
Infectious disease area:
- UTI
- STI
- BSI
- RTI
- GII
- SSTI
- CNSI
- IAI
- SSI
Geographic origin:
- Eurasia
- North America
- South America
- Africa
- Oceania
– technological know-how
– established position on diagnostic and/or R&D market
– distribution channels
– interest to further develop technology
– interest in new clinical indications
Resistell is a startup developing nanomotion technology platform for phenotypic Antimicrobial Susceptibility Testing and analysis of cell metabolism.
Resistell’s nanomotion based AST is under development for multiple indications, including blood stream infections, UTI, TB, Chlamydia and many other. In addition we offer our technology for research on cells’ metabolism.
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!